A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer
Public ClinicalTrials.gov record NCT02387996. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Single Arm Clinical Trial of Nivolumab (BMS-936558) in Subjects With Metastatic or Unresectable Urothelial Cancer Who Have Progressed or Recurred Following Treatment With a Platinum Agent
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose the study is to measure the effect of nivolumab (BMS-936558) in reducing tumor size in subjects with metastatic or unresectable bladder cancer.
Study identification
- NCT ID
- NCT02387996
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 270 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 9, 2015 (Actual)
- Primary completion
- Apr 15, 2016 (Actual)
- Completion
- Nov 12, 2021 (Actual)
- Last update posted
- Nov 1, 2022
2015 – 2021
United States locations
- U.S. sites
- 19
- U.S. states
- 16
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0013 | Phoenix | Arizona | 85054 | — |
| Local Institution - 0012 | Duarte | California | 91010-3000 | — |
| Pacific Hematology Oncology Associates | San Francisco | California | 94115 | — |
| Local Institution - 0016 | Aurora | Colorado | 80045 | — |
| University Cancer Blood Ctr | Athens | Georgia | 30607 | — |
| Ft. Wayne Med Onco-Hema Inc | Fort Wayne | Indiana | 46804 | — |
| Local Institution - 0030 | Indianapolis | Indiana | 46202 | — |
| Local Institution - 0052 | Iowa City | Iowa | 55242 | — |
| Crescent City Research Consortium, LLC | Marrero | Louisiana | 70072 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201-2014 | — |
| GU Research Network, LLC | Omaha | Nebraska | 68130 | — |
| Local Institution - 0028 | New York | New York | 10029 | — |
| Local Institution - 0004 | Charlotte | North Carolina | 28204 | — |
| Local Institution - 0051 | Portland | Oregon | 97213 | — |
| Local Institution - 0029 | Philadelphia | Pennsylvania | 19111-2412 | — |
| Local Institution - 0059 | Pittsburgh | Pennsylvania | 15212-0000 | — |
| Erlanger Oncology & Hematology - Univ. of TN | Chattanooga | Tennessee | 37404 | — |
| Local Institution - 0001 | Houston | Texas | 77030 | — |
| Local Institution - 0036 | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02387996, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 1, 2022 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02387996 live on ClinicalTrials.gov.